Market Access Views & Analysis

Views & Analysis

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

Market Access

Preparing for the pharma fraud enforcement surge

Here is what robust, risk-based compliance looks like in 2026.

Market Access

Changing Faces: Boards of Directors and Advisory Boards, May...

The latest Board moves reflect a focus on experience in commercialisation, corporate governance, and therapeutic development.

Market Access

A dynamic moment for pharma pricing: Insights from PPIC

At PPIC in Basel, pharma pricing experts discussed how policy changes and AI advances are altering the dynamics of pharmaceutical pricing and access.

Market Access

Company Profile: Acumetis

Acumetis is a global expert commercialisation partner purposefully built to help life sciences companies win in the age of connectivity.

Why global pharmaceutical reforms are quietly redirecting ra...

Policy in Focus: What’s new with CMS drug price negotiation,...

Preparing for the pharma fraud enforcement surge

Changing Faces: Boards of Directors and Advisory Boards, May...

A dynamic moment for pharma pricing: Insights from PPIC

Company Profile: Acumetis

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks